Abstract 649P
Background
AA is a rare malignancy with a predilection for peritoneal metastases without hematogenous or lymphatic metastases. Despite this, AA is treated with chemotherapy similar to colorectal cancer. Studies suggest inefficacy of these regimens for many AA patients supporting the likelihood of a unique genomic landscape.
Methods
WES of tumor tissue was performed as part of personalized circulating tumor DNA (ctDNA) testing (SignateraTM) in 855 patients with AA. Tumor mutational burden (TMB) and microsatellite instability (MSI) were assessed; Kyoto Encyclopedia of Genes and Genomes (KEGG) network analysis was performed. WES data on stage-matched colon (CC, N=833) and rectal cancer tissues (RC, N=841) were compared with AA.
Results
A total of 98,310 variants were identified from 855 AA tumor tissues (median 132.5 variants/tumor). AA had lower TMB (median: 2.14 Muts/Mb) than RC or CC (median: 3.55 and 4.31 Muts/Mb, respectively). Only 1.3% (11/855) of the AA were MSI-high, compared to RC (2.5%) and CC (16.76%). Comparison of frequently mutated genes highlighted that AA has much less frequent APC and TP53 and more frequent GNAS mutations. Despite differences in driver mutations and overall lower TMB, the mutational signatures for AA, CC, and RC were similar with SBS1 (clock-like) and SBS6 (MMR-deficient) being predominant in each tumor type. Co-mutation analysis identified a dense interaction network of 805 co-occurring or mutually exclusive interactions highlighted by connections between Wnt, Ras-MAPK, and DNA repair pathways. Copy number analysis identified that AA has less aneuploidy relative to CC or RC, however, within AA, TP53 mutation was associated with significantly higher aneuploidy relative to wildtype. Interestingly, TP53 mutations were also associated with detectable ctDNA in AA (44.6% vs. 24.9%, p<0.001), but not in CC or RC.
Conclusions
WES data on AA reveals important differences in driver somatic mutations, CNV, and co-mutational networks compared to CC and RC. This is the first large-scale genomic profiling of AA, establishing the genetic landscape of this rare and orphan disease. Future studies should focus on AA-specific treatments rather than the extrapolated CC/RC experience.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
S. Rivero-Hinojosa: Financial Interests, Personal, Stocks/Shares: Natera; Financial Interests, Personal, Full or part-time Employment: Natera. V. Aushev, A. Jurdi, M.C. Liu: Financial Interests, Personal, Full or part-time Employment: Natera, Inc.; Financial Interests, Personal, Stocks/Shares: Natera, Inc. All other authors have declared no conflicts of interest.
Resources from the same session
780P - Role of BRCA1 promotor methylation in homologous recombination deficiency (HRD) in high-grade ovarian cancer
Presenter: Heidelinde Fiegl
Session: Poster session 11
781P - Chemotherapy sensitivity score based on ex vivo 3D tumour testing to predict clinical response for ovarian cancer patients
Presenter: Janneke Walraven
Session: Poster session 11
782P - Correlation between chemotherapy response score (CRS) and germline BRCA1/2 (gBRCA) status in women diagnosed with FIGO stage IIIC/IV high-grade serous ovarian cancer (HGSOC)
Presenter: Daniel Netto
Session: Poster session 11
783P - The role of JARID1B in ovarian cancer
Presenter: Katharina Leitner
Session: Poster session 11
784P - HPV integration promotes HPV carcinogenesis via remodeling chromatin interactions between universal stripe factors and super-enhancer in HPV-related carcinoma
Presenter: Canhui Cao
Session: Poster session 11
785P - The predictive role of circulating exosomal PD-L1 in cervical cancer immunotherapy
Presenter: Wenjie Tang
Session: Poster session 11
786P - Antitumor activity of farletuzumab ecteribulin in a panel of endometrial cancer patient-derived xenografts with four different molecular subtypes
Presenter: Kosei Hasegawa
Session: Poster session 11
787P - A NGS panel for molecular classification of endometrial carcinoma
Presenter: Hao Wen
Session: Poster session 11
788P - Molecular profiling of p53 mutant endometrial cancer reveals distinct subgroups with opportunities for personalized therapeutic approaches
Presenter: Felix Blanc-Durand
Session: Poster session 11
789P - Real-world (RW) duration of treatment in first-line maintenance (1Lm) niraparib monotherapy in epithelial ovarian cancer (EOC): CHAR1ZMA study
Presenter: Floor Backes
Session: Poster session 11